BioSpace News Archive

GSK-Backed LifeMine Nets $175M and More Financing News

Read on to learn more about three Series B and C financing rounds in the areas of genetically encoded small molecules, artificial intelligence (AI) and immuno-oncology (IO).

March 23, 2022
·
3 min read
·
Mark Terry
Drug Development

Brain Implant Gives ALS Patient A Voice: “I Love My Cool Son”

A man paralyzed from amyotrophic lateral sclerosis (ALS) now has the ability to spell out his thoughts, thanks to an implanted electrode device that reads his brain signals.

March 23, 2022
·
3 min read
·
Hannah Chudleigh
Policy

Fraud Trial of Former Theranos Executive Ramesh’ Sunny’ Balwani Begins

Like Elizabeth Holmes, Ramesh Balwani faces multiple counts of fraud related to the business practices of Theranos.

March 23, 2022
·
2 min read
·
Alex Keown
Deals

FUJIFILM Enhances Life Sciences Arm with Shenandoah Buy

Shenandoah Biotechnology is a Warminster, Pennsylvania-based firm that manufactures recombinant proteins, including growth factors and cytokines.

March 23, 2022
·
2 min read
·
Vanessa Doctor, RN
Drug Development

Pfizer Lining Up New UC Drug, Former Employees Launch Counter Suit

Pfizer is lining up a potential New Drug Application for an ulcerative colitis treatment for patients who are not seeing an improvement in their condition from currently available options.

March 23, 2022
·
3 min read
·
Alex Keown
Drug Development

Neurana, Aurobindo and ORIC Face Tough Decisions, Layoffs

Neurana Pharmaceuticals is facing dire financial straits following the failure of its Phase III treatment for muscle spasm relief associated with an acute, painful musculoskeletal condition.

March 23, 2022
·
2 min read
·
Alex Keown
Drug Development

Global Roundup: Oryzon Genomics, AEterna Zentaris, CanSino and Telix

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

March 23, 2022
·
5 min read
·
Alex Keown
Business

Merck Bids Fond Farewell to Roy Baynes who Joins Eikon

Merck has announced the retirement of Dr. Roy D. Baynes, head of global clinical development and chief medical officer of Merck Research Laboratories.

March 23, 2022
·
3 min read
·
Hayley Shasteen
Drug Development

4D Pharma Hits Efficacy Target in Renal Cell Carcinoma Trial

The 4D pharma has shared positive interim results from its Phase I/II study of a combination therapeutic for the treatment of renal cell carcinoma (RCC).

March 23, 2022
·
3 min read
·
Hayley Shasteen
Money on the Move: March 16-22

Most major money moves this week were related to immune therapy companies, including rounds of funding for T cell therapies, allergy therapies and immunomodulation platforms.

March 23, 2022
·
2 min read
·
Hannah Chudleigh